Press Releases | EyePoint Pharmaceuticals

Year

pSivida Announces Resubmission of New Drug Application for ILUVIEN® Mar 27, 2014 WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the New Drug Application for ILUVIEN for the treatment of chronic Diabetic Macular Edema has been Read more
pSivida Corp. Announces $7.0 Million Investment by RA Capital Mar 13, 2014 WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV ) (ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, announced today that RA Capital has entered into a securities purchase agreement with the Company to invest Read more
pSivida Announces ILUVIEN® for DME Accepted by National Health Service Scotland Feb 10, 2014 WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the Scottish Medicines Consortium (SMC) has accepted ILUVIEN® for use within the National Health Read more
pSivida Corp. Reports Second Quarter 2014 Results Feb 07, 2014 WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced financial results for its second quarter ended December 31, 2013 . Read more
pSivida CEO to Present at 16th Annual BioCEO & Investor Conference February 12 Feb 06, 2014 WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV)(ASX:PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that Dr. Paul Ashton , President and CEO, will present at the 16 th Annual BioCEO & Investor Conference , Read more
pSivida CEO to Present at 16th Annual BioCEO & Investor Conference February 11 Feb 06, 2014 WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV)(ASX:PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that Dr. Paul Ashton , President and CEO, will present at the 16 th Annual BioCEO & Investor Conference , Read more
pSivida Corp Announces Second Quarter 2014 Financial Results Release Date and Conference Call Information Jan 30, 2014 WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that its financial results for the second quarter of fiscal year 2014 will be released after the market Read more
pSivida Corp. Reports First Orders for ILUVIEN® Shipped for U.K. National Health Service Hospitals Less Than Seven Weeks After Final NICE Guidance Jan 13, 2014 First NHS patient treated on January 10, 2014 WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that its licensee Alimera Sciences has shipped initial Read more
pSivida Corp. Reports FDA Labeling Discussions for ILUVIEN® for DME; Advisory Committee Meeting No Longer Necessary Dec 18, 2013 WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that its licensee Alimera Sciences has entered into labeling discussions with the U.S. Read more
pSivida Executives to Present at Two Upcoming Investor Conferences This Month Dec 04, 2013 WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that company management will present at two upcoming investor conferences: Lori Freedman , vice president Read more
pSivida Reports ILUVIEN® to Be Funded by UK's National Health Service for Treatment of Pseudophakic Chronic DME Patients Following Issuance of Final NICE Guidance Dec 02, 2013 WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that on November 27, 2013 , the United Kingdom's National Institute for Health and Care Excellence (NICE) Read more
pSivida Corp. Reports First Quarter 2014 Results Nov 12, 2013 WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced financial results for its first quarter ended September 30, 2013 . Read more
pSivida Corp Announces First Quarter 2014 Financial Results Release Date and Conference Call Information Nov 05, 2013 WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained release drug delivery products for treatment of back-of-the-eye diseases, today announced that its financial results for the first quarter of fiscal year 2014 will be released after the Read more
pSivida Reports Complete Response Letter From FDA for ILUVIEN® Oct 18, 2013 WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a specialty pharmaceutical company that is a leader in developing sustained release drugs for treatment of back-of-the-eye diseases, today announced that its licensee Alimera Sciences, Inc. Read more
pSivida Announces That U.K.'s NICE Recommends ILUVIEN® for Chronic Diabetic Macular Edema in Pseudophakic Eyes; NHS Reimbursement Expected to Follow Sep 30, 2013 WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a specialty pharmaceutical company that is a leader in developing sustained release drugs for treatment of back-of-the-eye diseases, today announced that the United Kingdom's National Institute for Health and Care Read more
pSivida to Present at 4th Annual Conference on Biosimilars & Biobetters Sep 27, 2013 WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV ), a specialty pharmaceutical company that is a leader in developing sustained release drugs for treatment of back-of-the-eye diseases, will present at the 4 th Annual Biosimilars & Biobetters Conference being held October 1 and 2 in Read more
pSivida Corp. Reports Fourth Quarter and Fiscal Year 2013 Results Sep 25, 2013 WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced financial results for its fourth quarter and fiscal year ended June 30, 2013 . Read more
pSivida Corp. Announces Fourth Quarter and Fiscal Year 2013 Financial Results Release Date and Conference Call Information Sep 18, 2013 WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that its financial results for the fourth quarter and fiscal year 2013 will be released after the Read more
pSivida to Present At Two Investment Conferences in September Sep 04, 2013 WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV ), a specialty pharmaceutical company that is a leader in developing sustained release drugs for treatment of back-of-the-eye diseases, will present at two upcoming investor conferences in September. Read more
pSivida CEO to Discuss Sustained Delivery of Antibodies in Ophthalmology and Systemic Disease at International Symposium on Integrated Functionalities Jul 29, 2013 WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV), a specialty pharmaceutical company that is a leader in developing sustained release drugs for treatment of back-of-the-eye diseases, has announced that pSivida President and Chief Executive Officer, Paul Ashton , Ph.D., will speak Read more

pSivida Announces Resubmission of New Drug Application for ILUVIEN®

Mar 27, 2014

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the New Drug Application for ILUVIEN for the treatment of chronic Diabetic Macular Edema has been

pSivida Corp. Announces $7.0 Million Investment by RA Capital

Mar 13, 2014

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV ) (ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, announced today that RA Capital has entered into a securities purchase agreement with the Company to invest

pSivida Announces ILUVIEN® for DME Accepted by National Health Service Scotland

Feb 10, 2014

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the Scottish Medicines Consortium (SMC) has accepted ILUVIEN® for use within the National Health

pSivida Corp. Reports Second Quarter 2014 Results

Feb 07, 2014

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced financial results for its second quarter ended December 31, 2013 .

pSivida CEO to Present at 16th Annual BioCEO & Investor Conference February 12

Feb 06, 2014

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV)(ASX:PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that Dr. Paul Ashton , President and CEO, will present at the 16 th Annual BioCEO & Investor Conference ,

pSivida CEO to Present at 16th Annual BioCEO & Investor Conference February 11

Feb 06, 2014

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV)(ASX:PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that Dr. Paul Ashton , President and CEO, will present at the 16 th Annual BioCEO & Investor Conference ,

pSivida Corp Announces Second Quarter 2014 Financial Results Release Date and Conference Call Information

Jan 30, 2014

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that its financial results for the second quarter of fiscal year 2014 will be released after the market

pSivida Corp. Reports First Orders for ILUVIEN® Shipped for U.K. National Health Service Hospitals Less Than Seven Weeks After Final NICE Guidance

Jan 13, 2014

First NHS patient treated on January 10, 2014 WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that its licensee Alimera Sciences has shipped initial

pSivida Corp. Reports FDA Labeling Discussions for ILUVIEN® for DME; Advisory Committee Meeting No Longer Necessary

Dec 18, 2013

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that its licensee Alimera Sciences has entered into labeling discussions with the U.S.

pSivida Executives to Present at Two Upcoming Investor Conferences This Month

Dec 04, 2013

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that company management will present at two upcoming investor conferences: Lori Freedman , vice president

pSivida Reports ILUVIEN® to Be Funded by UK's National Health Service for Treatment of Pseudophakic Chronic DME Patients Following Issuance of Final NICE Guidance

Dec 02, 2013

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that on November 27, 2013 , the United Kingdom's National Institute for Health and Care Excellence (NICE)

pSivida Corp. Reports First Quarter 2014 Results

Nov 12, 2013

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced financial results for its first quarter ended September 30, 2013 .

pSivida Corp Announces First Quarter 2014 Financial Results Release Date and Conference Call Information

Nov 05, 2013

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained release drug delivery products for treatment of back-of-the-eye diseases, today announced that its financial results for the first quarter of fiscal year 2014 will be released after the

pSivida Reports Complete Response Letter From FDA for ILUVIEN®

Oct 18, 2013

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a specialty pharmaceutical company that is a leader in developing sustained release drugs for treatment of back-of-the-eye diseases, today announced that its licensee Alimera Sciences, Inc.

pSivida Announces That U.K.'s NICE Recommends ILUVIEN® for Chronic Diabetic Macular Edema in Pseudophakic Eyes; NHS Reimbursement Expected to Follow

Sep 30, 2013

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a specialty pharmaceutical company that is a leader in developing sustained release drugs for treatment of back-of-the-eye diseases, today announced that the United Kingdom's National Institute for Health and Care

pSivida to Present at 4th Annual Conference on Biosimilars & Biobetters

Sep 27, 2013

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV ), a specialty pharmaceutical company that is a leader in developing sustained release drugs for treatment of back-of-the-eye diseases, will present at the 4 th Annual Biosimilars & Biobetters Conference being held October 1 and 2 in

pSivida Corp. Reports Fourth Quarter and Fiscal Year 2013 Results

Sep 25, 2013

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced financial results for its fourth quarter and fiscal year ended June 30, 2013 .

pSivida Corp. Announces Fourth Quarter and Fiscal Year 2013 Financial Results Release Date and Conference Call Information

Sep 18, 2013

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that its financial results for the fourth quarter and fiscal year 2013 will be released after the

pSivida to Present At Two Investment Conferences in September

Sep 04, 2013

pSivida CEO to Discuss Sustained Delivery of Antibodies in Ophthalmology and Systemic Disease at International Symposium on Integrated Functionalities

Jul 29, 2013

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV), a specialty pharmaceutical company that is a leader in developing sustained release drugs for treatment of back-of-the-eye diseases, has announced that pSivida President and Chief Executive Officer, Paul Ashton , Ph.D., will speak

First page
Previous page
…
Page 15
Page 16
Page 17
Page 18
Current page 19
Page 20
Page 21
Page 22
Page 23
…
Next page
Last page

Displaying 361 - 380 of 545

News releases are posted on the Company's website as soon as possible after the release over the news wire. You should view the Financial Information section and most recent SEC Filings in the Investors section to receive the most current information made available by EyePoint Pharmaceuticals, Inc.